Features
NEWS BRIEFS
IOP-lowering Treatment Receives FDA Approval
A Slow Game
Glaucoma physicians must be dedicated to a lifetime of caring about our patients
By Robert D. Fechtner, MD
Ocular Surface Disease and Glaucoma
Improved detection and treatment of OSD may lead to better clinical outcomes for glaucoma patients
By Robert D. Fechtner, MD
Tele-glaucoma: The Next Frontier
How this technology can help improve care for many patients
By Albert S. Khouri, MD
Widefield OCT Improves Glaucoma Management
Ganglion cell complex analysis provides a more comprehensive picture of disease status
By Robert Rothstein, MD
Moving to the Front of the Line
How glaucoma fellowships transformed from last pick to first pick
By Alena Reznik, MD
Glaucoma in Africa
A strategic approach to preventing blindness
By Tony Realini, MD, MPH, Adeyinka Ashaye, MD, MSc
ECP in Refractory Glaucoma Patients
How this existing therapy is creating new treatment opportunities for a wider range of patients
By Juan Carlos Izquierdo, MD
The Significance of ECP in Today’s Glaucoma Management
A pressure-lowering workhorse emerges as potent pairing with MIGS
By ERIN MURPHY, CONTRIBUTING
Keeping a Closer Watch on IOP
New technologies for frequent self-measurement open a new era in glaucoma care
By Desiree Ifft, Contributing
Departments
Samples and Free Products
What does CMS, FDA, and AMA have to say about them?
By Kevin J. Corcoran, COE, CPC, CPMA, FNAO